STIF 53.700 € (+2,29 %)
HAVAS 16.700 € (+1,21 %)
AYVENS 11.200 € (+1,27 %)
MAUNA KEA TECH 0.178 € (+0,91 %)
EMEIS 14.980 € (+1,90 %)
OPMOBILITY 15.660 € (+2,35 %)
CVC CAPITAL 13.340 € (+2,30 %)
FDJ UNITED 23.140 € (+0,43 %)
ATON 0.014 € (-4,23 %)
B.COM.PORTUGUES 0.984 € (+2,14 %)
FIGEAC AERO 10.780 € (+1,13 %)
SOITEC 178.600 € (+0,70 %)
THEON INTERNAT 31.540 € (-1,13 %)
SHELL PLC 36.695 € (-1,12 %)
MERSEN 39.720 € (+1,85 %)
RENAULT 28.680 € (+2,94 %)
SOCIETE GENERALE 70.800 € (+2,91 %)
2CRSI 48.900 € (+4,71 %)
WORLDLINE 0.354 € (+10,60 %)
AIRBUS 173.620 € (+2,42 %)
DSM FIRMENICH AG 70.640 € (-1,20 %)
MICHELIN 31.910 € (+1,27 %)
DASSAULT AVIATION 295.800 € (+1,51 %)
ADYEN 981.700 € (+2,48 %)
MEDIANTECHNOLOGIES 5.550 € (+2,97 %)
ASM INTERNATIONAL 907.600 € (+0,75 %)
ASML HOLDING 1 421.600 € (+0,89 %)
SES 8.800 € (-1,68 %)
ELIOR GROUP 2.002 € (+1,11 %)
KALRAY 12.280 € (+11,03 %)
SAFRAN 298.400 € (+4,70 %)
HAL TRUST 176.000 € (+0,46 %)
NEDAP 94.300 € (-0,32 %)
VOPAK 47.300 € (+1,72 %)
ABN AMRO BANK N.V. 34.320 € (+1,12 %)
ADP 112.000 € (+2,56 %)
HAFFNER ENERGY 0.225 € (+26,27 %)
EKINOPS 3.160 € (+1,94 %)
EIFFAGE 123.850 € (+2,36 %)
ESSILORLUXOTTICA 175.500 € (+1,30 %)
ACCOR 46.610 € (+4,09 %)
ALTAREA 109.800 € (+1,67 %)
PUBLICIS GROUPE SA 83.900 € (+0,72 %)
RANDSTAD NV 26.170 € (+0,27 %)
SCHNEIDER ELECTRIC 274.000 € (+1,84 %)
SANOFI 76.600 € (-0,36 %)
PROSUS 40.360 € (+3,33 %)
UNIBAIL-RODAMCO-WE 98.600 € (+1,02 %)
MAAT PHARMA 3.110 € (-4,45 %)
CREDIT AGRICOLE 17.565 € (+1,77 %)
PHARMING GROUP 1.175 € (+5,05 %)
VOLTALIA 8.520 € (+5,19 %)
ENGIE 27.350 € (+0,66 %)
ALTRI SGPS 5.340 € (+1,91 %)
IPSEN 161.400 € (+0,75 %)
AIR FRANCE -KLM 11.010 € (+7,36 %)
ING GROEP N.V. 26.865 € (+1,63 %)
CAPGEMINI 104.600 € (+1,45 %)
GENFIT 8.650 € (+1,53 %)
SBM OFFSHORE 34.500 € (-0,92 %) |
13/05/2026 22:01
Amdocs Limited Reports Second Quarter Fiscal 2026 ResultsRevenue of $1.17 Billion, up 3.9% YoY as Reported and up 2.2% YoY in Constant Currency(1) Expects Fiscal 2026 Revenue Growth Outlook of 2.6%-4.6% YoY as Reported Reiterates Midpoint of Fiscal 2026 Revenue Growth Outlook in Constant Currency(1) while Tightening Expected Range to 2.0%-4.0% YoY Announces Retirement of Long-Serving CFO and Appointment of Internal CFO Successor Second Quarter Fiscal 2026 Highlights (All comparisons are against same quarter of the prior year, unless otherwise stated)
(1) Revenue on a constant currency basis assumes exchange rates in the current period were unchanged from the prior period JERSEY CITY, NJ / ACCESS Newswire / May 13, 2026 / Amdocs Limited (NASDAQ:DOX), a leading provider of software and services to communications and media companies, today reported operating results for the three months ended March 31, 2026. "I'm excited to be leading Amdocs forward in the agentic era, as our vision is to become the primary partner of choice to turn the agentic opportunity into reality for our customers. We believe Amdocs is uniquely positioned to lead due to our deep industry knowledge and telco domain expertise, engineering and innovation pedigree, mission critical systems transformation leadership and our outcome-based business model. To realize our vision, we are aiming to move towards an agentic and automated portfolio, tailor agentic customer roadmaps, leverage strategic partnerships, and internally transform the way we operate. While we are continuing to refine our strategy, we are already seeing initial commercial engagements with the launch of aOS- Amdocs' agentic operating system for telco. We are building this strategy on our strong business foundations, as demonstrated by solid Q2 results which show healthy sales, strong customer relationships and consistent operating execution," said Shimie Hortig, president and chief executive officer of Amdocs Management Limited. "Project delivery continued as a defining strength for Amdocs this quarter, as reflected by many production milestones achieved for AT&T, Vodafone Germany and other flagship customers worldwide. Profitability improved year-over-year, demonstrating our continued focus on operational excellence and automation, and we generated healthy free cash flow of which we returned more than 100% to shareholders though share repurchases and dividend payments," said Tamar Rapaport-Dagim, chief financial officer and chief operating officer of Amdocs Management Limited. Hortig continued, "I'm pleased with our financial and operational progress for the fiscal year to date, and while we are closely monitoring macroeconomic developments and customer spending behavior in the current climate, we are on track to achieve our fiscal 2026 financial guidance." Hortig concluded, "On behalf of the Board and the entire leadership team, I want to thank Tamar for her exceptional leadership, partnership and dedication over the past 22 years. Throughout her tenure, Tamar has played a critical role in strengthening our financial foundation, leading operational excellence, supporting our strategic growth and helping position the company for long-term success. We are deeply grateful for her many contributions and wish her the very best. We are very pleased to appoint Tal Rozenfeld as our next Chief Financial Officer. Tal brings deep financial expertise, strong operational and business knowledge and a proven track record of leadership. Tal has been an important part of our finance and leadership team, and we are confident he will play a key role in driving the next phase of Amdocs' growth and execution." Revenue (All comparisons are against same quarter as the prior year, unless otherwise stated )
Net Income and Earnings Per Share
Capital Allocation & Liquidity
Twelve-month Backlog Twelve-month backlog was $4.28 billion at the end of the second quarter of fiscal 2026, up approximately 2.6% as compared to last year's second fiscal quarter. Twelve-month backlog includes anticipated revenue related to contracts, estimated revenue from managed services contracts, letters of intent, maintenance and estimated on-going support activities. Third Quarter Fiscal Year 2026 Outlook
Full Year Fiscal 2026 Outlook
The forward-looking statements regarding our third fiscal quarter 2026 and full year fiscal 2026 guidance take into consideration the Company's current expectations regarding macroeconomic, geopolitical and industry specific risks and various uncertainties and certain assumptions, some of which we will discuss on our earnings conference call. However, we note that market dynamics continue to shift rapidly and we cannot predict all possible outcomes, including those resulting from certain geopolitical events, the current inflationary environment, changes to trade policies including tariffs and trade restrictions and the resulting impact on economic activities (as our outlook assumes current economic conditions do not deteriorate significantly due to trade policy or other macro factors), global or regional events, and the prevailing level of macro-economic, business and operational uncertainty, including customer spending behavior which have created, and continue to create, a significant amount of uncertainty, or from current and potential customer consolidation or their other strategic corporate activities. See "Forward-Looking Statements" below. Conference Call and Earnings Webcast Presentation Details Amdocs will host a conference call and earnings webcast presentation on May 13, 2026 at 5:00 p.m. Eastern Time to discuss the Company's second quarter of fiscal 2026 results. To participate in the call, please register here to receive the dial-in numbers and unique access PIN. The conference call and webcast will also be carried live on the Internet and may be accessed via the Amdocs website at https://investors.amdocs.com. Presentation slides will be available shortly before the webcast. Non-GAAP Financial Measures
Free cash flow(2) equals cash generated by operating activities less net capital expenditures. These non-GAAP financial measures are not in accordance with, or an alternative for, generally accepted accounting principles and may be different from non-GAAP financial measures used by other companies. In addition, these non-GAAP financial measures are not based on any comprehensive set of accounting rules or principles. Amdocs believes that non-GAAP financial measures have limitations in that they do not reflect all of the amounts associated with Amdocs' results of operations as determined in accordance with GAAP and that these measures should only be used to evaluate Amdocs' results of operations in conjunction with the corresponding GAAP measures. Amdocs believes that the presentation of non-GAAP financial measures, including non-GAAP diluted earnings per share, free cash flow(2), revenue on a constant currency(1) basis, non-GAAP cost of revenue, non-GAAP research and development, non-GAAP selling, general and administrative, non-GAAP operating income, non-GAAP operating margin, non-GAAP interest and other expenses, net, non-GAAP income taxes, non-GAAP effective tax rate, non-GAAP net income, non-GAAP net income attributable to Amdocs Limited and non-GAAP diluted earnings per share growth when shown in conjunction with the corresponding GAAP measures, provides useful information to investors and management regarding financial and business trends relating to its financial condition and results of operations, as well as the net amount of cash generated by its business operations after taking into account capital spending required to maintain or expand the business. For its internal budgeting process and in monitoring the results of the business, Amdocs' management uses financial statements that do not include amortization of purchased intangible assets and other acquisition-related costs, changes in certain acquisition-related liabilities measured at fair value, restructuring and unusual charges or benefits, equity-based compensation expense, other and related tax effects. Amdocs' management also uses the foregoing non-GAAP financial measures, in addition to the corresponding GAAP measures, in reviewing the financial results of Amdocs. In addition, Amdocs believes that significant groups of investors exclude these items in reviewing its results and those of its competitors, because the amounts of the items between companies can vary greatly depending on the assumptions used by an individual company in determining the amounts of the items. Amdocs further believes that, where the adjustments used in calculating non-GAAP diluted earnings per share are based on specific, identified amounts that impact different line items in the Consolidated Statements of Income (including cost of revenue, research and development, selling, general and administrative, operating income, interest and other expenses, net, income taxes and net income), it is useful to investors to understand how these specific line items in the Consolidated Statements of Income are affected by these adjustments. Please refer to the Reconciliation of Selected Financial Metrics from GAAP to Non-GAAP tables below. Supporting Resources
About Amdocs Amdocs helps the world's leading communications and media companies deliver exceptional customer experiences through reliable, efficient, and secure operations at scale. We provide software products and services that embed intelligence into how work runs across business, IT, and network domains - delivering measurable outcomes in customer experience, network performance, cloud modernization, and revenue growth. With our talented people, and more than 40 years of experience running mission-critical systems around the globe, Amdocs runs billions of transactions daily. Our technology is relied on every day, connecting people worldwide and advancing a more inclusive, connected world. Together, we help those who shape the future to make it amazing. Amdocs is listed on the NASDAQ Global Select Market (NASDAQ:DOX) and reported revenue of $4.53 billion in fiscal 2025. For more information, visit www.amdocs.com. Forward-Looking Statements This press release includes information that constitutes forward-looking statements made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995, including statements about Amdocs' strategy, including with respect to artificial intelligence and agentic opportunities, growth, financial outlook, and business results in future quarters and years. Although we believe the expectations reflected in such forward-looking statements are based upon reasonable assumptions, we can give no assurance that our expectations will be obtained or that any deviations will not be material. Such statements involve risks, uncertainties, and other important factors that may cause future results to differ materially from those anticipated. These risks include, but are not limited to, the effects of general macroeconomic conditions, prevailing level of macroeconomic, business and operational uncertainty, including as a result of geopolitical events or other regional events or pandemics, changes to trade policies including tariffs and trade restrictions, as well as the current inflationary environment, and the effects of these conditions on the Company's customers' businesses and levels of business activity, including the effect of the current economic uncertainty and industry pressure on the spending decisions of the Company's customers, Amdocs' ability to grow in the business markets that it serves, Amdocs' ability to successfully integrate acquired businesses, adverse effects of market competition, rapid technological shifts that may render the Company's products and services obsolete, security incidents, including breaches and cyberattacks to our systems and networks and those of our partners or customers, potential loss of a major customer, our ability to develop long-term relationships with our customers, our ability to successfully and effectively implement artificial intelligence and Generative AI in the Company's offerings and operations, and risks associated with operating businesses in the international market. Amdocs may elect to update these forward-looking statements at some point in the future; however, Amdocs specifically disclaims any obligation to do so. These and other risks are discussed at greater length in Amdocs' filings with the Securities and Exchange Commission, including in our Annual Report on Form 20-F for the fiscal year ended September 30, 2025, filed on December 15, 2025, and our Form 6-K furnished for the first quarter of fiscal 2026 on February 17, 2026. Contact: AMDOCS LIMITED Consolidated Statements of Income
Source : Webdisclosure.com |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Cotations différées d'au moins 15 minutes (Paris, Amsterdam, Bruxelles, Lisbonne).
Cotations à la clôture (Francfort, New-York, Londres, Zurich).
Flux de cotations : Euronext (Places Euronext et Cours des Devises).
Bourse : technologie Cote Boursière